Surgery of Thymus Gland
- Author: Said Fadi Yassin, MD; Chief Editor: Jeffrey C Milliken, MD more...
The origin of the name of the thymus gland is unclear. The name may have been derived from a perceived resemblance between the gland and the herb thyme; alternatively, it may have been derived from the Greek word thymos, meaning soul or heart, presumably in reference to the intimate anatomic relation between the thymus and the heart.
The first description of the thymus gland was by the Italian anatomist Giacomo da Capri (1470-1550). The Swiss physician Felix Platter reported the first case of suffocation due to hypertrophy of the thymus gland in 1614. The first indication of an association between myasthenia and the thymus gland was in 1901, when the German neurologist Hermann Oppenheim reported a tumor found growing from the thymic remnant at necropsy in a patient with myasthenia.
The report by Oppenheim led the German thoracic surgeon Ernst Sauerbruch to perform a cervical thymectomy in 1911 on a 20-year-old woman with a radiologically enlarged thymus who had myasthenia. He reported that the myasthenia was markedly improved after the surgery, but resection of thymomas in patients with myasthenia at that time was accompanied by a high mortality. In 1936, Alfred Blalock performed a transsternal total thymectomy during a remission period from severe myasthenia. By 1944, he had accumulated experience in 20 cases, firmly establishing the role of thymectomy in the treatment of these patients.
In mammals, the thymus gland develops from the ventral portion of the third branchial pouch as tubular primordia elongate caudally and fuse at the midline, losing their connection with the pharynx and leaving the definitive thymus in the mediastinum.
The thymus is the first lymphoid organ that develops. Normal peripheral lymph nodes depend on seeding by small lymphocytes from the thymus. The thymus reaches its greatest size at puberty, after which time it undergoes slow involution and both cortical and T lymphocytes are reduced in peripheral blood.
Anomalies of thymus
Cervical thymic cysts may form from persistent remnants of the tubular upper end of the primitive organ. This is an extremely rare clinical condition.
Undescended thymus can be bilateral, but it is more commonly unilateral on the left side. Undescended thymus is usually diagnosed in childhood.
Accessory thymus body along the line of embryonic descent is common but is not clinically significant (it may be found in 25% of the population).
Thymic agenesis is an autosomal recessive disease often associated with agenesis of the parathyroid glands (DiGeorge syndrome), which leads to early death from infections or cardiac defects. Thymus and parathyroid transplant are the only possible treatments.
In thymic aplasia, the thymus is small. Usually, reticular cells and large lymphocytes are present without the small lymphocyte and Hassall bodies. Thymus and fetal liver implants to reconstitute T- and B-cell function have met with some success.
The thymus is composed of two distinct lobes, each of which is surrounded by a collagenous capsule with septa that extend into the corticomedullary junction, dividing the cortex further into lobules.
Arterial supply to the thymus varies. It could be derived from the internal mammary artery, the inferior thyroid artery, and from these two plus the superior thyroid artery. A single vein frequently leaves each side of the medial lobe. The veins join to form a short, wide vein that drains into the left brachiocephalic vein. A lateral vein drains from the right side of the gland into the superior vena cava and from the left side into the left brachiocephalic vein.
A hypothalamic-thymic neural pathway has been suggested to explain the numerous neurologic, social, psychological, and environmental factors that have been shown to influence the thymic hormones and the immune system.
The thymus gland contains the following three major cell populations:
Epithelial cells are mainly responsible for the creation of the necessary microenvironments and their factors. They promote different steps of intrathymic T-cell differentiation and maturation. Previously, epithelial cells were referred to as pale and dark cells; the cortex contains pale cells, and the medulla contains both pale and dark cells. These cells are now categorized into the following six types, with intermediate gradation:
Type 1 - Subcapsular-perivascular cells
Type 2 - Pale epithelial cells, predominate in the outer cortex
Type 3 - Probably thymic nurse cells that have the unique feature of emperipolesis
Type 4 - Dark cells that are typical in the medulla
Type 5 - Undifferentiated cells that are typical in the medulla
Type 6 - Large medullary cells that are found around and in the Hassall corpuscles, characteristic of the medulla; may contain (in addition to epithelial cells) various cell types and have the ability to accumulate antigen
Three main morphologically distinct types of lymphoid cells of the adult human thymus exist,as follows:
These seem to correspond to the three functional subsets of thymocytes recognized by the identification of cluster of differentiation antigens (ie, classes I, II, and III). The human thymus, especially in the fetus, supports erythropoiesis and granulopoiesis. Mast cells are formed in the thymus throughout life.
Macrophages secrete a thymocyte-differentiating factor that is mitogenic and induces functional maturation of the thymocyte. Interdigitating cells have a role in determining which T-cell precursors (helper or killer) are activated during an immunologic challenge. Myoid cells demonstrate acetylcholine receptors and have a possible role in myasthenia gravis. They may have a role in expelling thymocytes from the glands.
The lymphocytes are attracted to the thymus by chemotactic factors of epithelial origin. After they colonize the epithelium, they may be bathed constantly by circulating self-antigens. These antigens enter the thymus by transcapsular route, a step believed to be critical in the process of learning and of self-recognition.
The thymic epithelium provides the principal signals of differentiation by direct cell contact (presentation of major histocompatibility complex [MHC]antigens) and intermediary of multiple hormones, including the following:
Thymopoietin - This hormone depresses neuromuscular transmission, induces T-cell markers, and has a role in the generation of cytotoxic T cells and prevention of autoimmunity 
Thymulin - This hormone stimulates most T-cell functions, provided that they are not too immature, in which case they would need concomitant direct contact with the thymic epithelium
Thymosin alpha 1
Hyperplasia is an increase in the volume of the thymus gland by formation of new cellular elements in a normal microscopic arrangement. Two morphological types exist: true hyperplasia and lymphofollicular hyperplasia.
True hyperplasia is characterized by an increase in both size and weight of the thymus. Thymic hyperplasia is a very rare pathology that presents clinically or radiologically as a mediastinal mass. It is divided into three clinicopathological subtypes, as follows:
Massive thymic hyperplasia
Thymic rebound in childhood and adolescence
Massive thymic hyperplasia is a rare pathologic finding, with only a few well-documented cases. Enlargement of the thymus, however, is common in infancy. The cause is unknown; it may be due to thymic hyperfunction or dysfunction related to the endocrine activity of the gland. Patients usually present with symptoms of irritation of the mediastinal structures; symptoms may range from none to respiratory distress.
Thymic rebound in childhood and adolescence is described in numerous conditions, such as recovery from severe thermal burns, cardiac surgery, tuberculosis, following treatment for different malignancies, and after discontinuance of oral steroids.
The functionally active thymus in childhood and adolescence may be susceptible to the fluctuation in corticosteroids levels, which is thought to be a causative factor in thymic hyperplasia (reversal of elevated endogenous corticosteroids in severe burns, withdrawal of exogenous corticosteroids in malignancy treatment).
Patient age ranges from 2-12 years. All reported cases were detected on routine chest radiograph with no other clinical or laboratory positive finding.
After malignancy, thymic hyperplasia could be confused radiologically with recurrence or metastasis.
Finally, thymic hyperplasia has been reported in association with sarcoidosis and endocrine abnormalities (thyrotoxicosis, hypothyroidism, Addison disease, acromegaly).
Leukocytosis, lymphocytosis, and hypogammaglobulinemia were reported, but blood test results may be completely normal. Chest radiography shows widening of the mediastinum; computed tomography (CT) shows the enlarged thymus.
A child with a newly-recognized anterior mediastinal mass could be observed carefully if he or she is thriving and most of the alternative diagnosis possibilities have been ruled out by appropriate clinical and laboratory examinations.
A brief course of steroids could be attempted if a corticosteroid-sensitive tumor could be ruled out. Steroids often shrink a hyperplastic thymus. If the steroid test is inconclusive or if hyperplasia persists for more than 2 years, a diagnostic mediastinoscopy is necessary. In a case involving a symptomatic or calcified mass, complete resection is needed to make the diagnosis and to rule out malignancy.
Lymphofollicular thymic hyperplasia
Lymphofollicular thymic hyperplasia is characterized by its histologic appearance, which is composed of lymph follicles with germinal centers similar to those in the lymph nodes in the medulla of a normal-sized thymus. The number of these follicles varies considerably from one patient to another and within different parts of the same gland, which explains why the diagnosis may be overlooked on single section or small biopsies.
Lymphofollicular thymic hyperplasia has been categorized in the following manner:
Chronic disseminated infections
Classification of Thymic Neoplasms
The histologic classification system proposed in 1999 by the World Health Organization (WHO) is the most recent classification, which recognizes the following six different types of thymic tumors :
Type A - Neoplastic spindle-shaped epithelial cells without atypia or neoplastic lymphocytes
Type AB - Tumors similar to type A but with a focus of neoplastic lymphocytes
Type B1 - Tumors that resemble normal thymic cortex with areas similar to thymic medulla
Type B2 - Scattered neoplastic epithelial cells with vesicular nuclei
Type B3 - Composed predominantly of epithelial cells that exhibit mild atypia
Type C - Thymic carcinoma
Previously, all of these tumors were designated as thymomas. Currently, they divided into two distinct categories, thymomas and thymic carcinomas.
A thymoma is a neoplasm consisting of cytologically bland thymic epithelial cells. Thymoma is the most common primary neoplasm of the mediastinum, accounting for 15% of all mediastinal masses. Patients are aged 40-60 years, with equal incidence in males and females. Thymomas present in 50% of the cases as anterior-superior mediastinal masses discovered incidentally on routine chest radiograph.
Twenty-five percent of patients describe vague chest problems. Patients may present with symptoms of thoracic structural displacement (cough, dyspnea, palpitation, dysphagia, superior vena cava syndrome, or substernal aching pain). In a few reported cases, thymoma presented as one of various paraneoplastic syndromes, such as myasthenia gravis, pure erythroid aplasia (poor prognosis), or acquired hypogammaglobulinemia. Rarely, thymoma occurs in an ectopic location (posterior mediastinum, pulmonary parenchyma, and the base of the neck).
Posteroanterior and lateral chest radiograph shows a small, rounded mediastinal mass. Approximately 15% of thymomas show calcification, usually amorphous patches. Clearly defined tumors smaller than 5 cm in diameter are likely to be noninvasive. On the other hand, more than 50% of tumors are larger than 8 cm, flat, irregular or poorly defined, and invasive.
Computed tomography (CT) of the thorax with contrast demonstrates the extension of the thymoma to the mediastinum or pleura. Noninvasive thymomas appear as round or oval, well-circumscribed masses within the thymus. Invasive tumors appear as irregular, ill-defined masses with obliteration of the tissue planes defined by mediastinal fat. About 30% of thymomas are invasive. CT is the best nonsurgical method of detecting extension to the pleura and transpleural spread and should encompass the whole thorax to the most inferior extent of the posterior diaphragmatic sulci and the abdomen, in case of diaphragmatic involvement.
Magnetic resonance imaging (MRI) is superior to CT in its ability to image coronal and sagittal planes in addition to the axial plane. Pneumomediastinography, venography, and arteriography rarely are used in current practice. Bone scan identifies bone metastases. Gallium-67 citrate is taken by lymphoma and may help in the differential diagnosis.
Fine-needle aspiration (FNA) biopsy may allow an outpatient diagnosis for planning definite treatment or nonoperative therapy in patients who are poor candidates for anesthesia. A high success rate was reported, with a pneumothorax rate as low as 6%. Nevertheless, in predominantly lymphocytic and spindle cell thymomas, ruling out a small-cell malignant lymphoma and mesenchymal lesions may be difficult.
Mediastinoscopy can be performed on an outpatient basis. It provides larger tissue samples.
Thymomas have a well-defined fibrous capsule with internal septation. They are composed of varying proportions of neoplastic epithelial cells and lymphocytes. Mitotic activity usually is scanty, and atypical mitoses are absent. Thymomas are divided into the following three types:
Predominantly epithelial (a special variant is spindle cell thymoma)
The most important factor in predicting the behavior of a thymoma is the clinical stage. The Masaoka system has gained wide acceptance and includes the following stages:
Stage I - Intact capsule
Stage II - Local invasion into the surrounding tissue
Stage IIa - Macroscopic invasion into surrounding fat or pleura
Stage IIb - Microscopic invasion into the capsule
Stage III - Gross invasion of the surrounding organs
Stage IVa - Disseminated disease, intrathoracic
Stage IVb - Lymphogenous or hematogenous extrathoracic metastasizing thymomas (extremely rare [<5%]; supposedly caused by embolic spread to the cervical lymph nodes, bones, liver, and brain)
Epidermal growth factor (EGF) receptor (EGFR) expression was found to be present in 83% of patients with thymomas and 50% of those with thymic carcinomas. C-kit was found to be positive in 73% of patients with thymic carcinomas and 5% of those with thymomas. p53 protein accumulation is present in 75% of patients with thymic carcinomas and correlates with more advanced stages and less resectability; however, mutations are infrequent.
These findings are valuable as prognostic and, potentially, preventive tools. They could also form a base for novel diagnostic and therapeutic approaches. Cases of dramatic response to imatinib in patients with metastatic thymic carcinoma and strong kit expression have already been reported.
Surgical resection is the mainstay of treatment.[12, 13, 14]
Thymic tumors are occasionally associated with pancytopenia, red cell hypoplasia, Cushing syndrome, Addison disease, and hypogammaglobulinemia. A proper workup should include investigation and correction of these abnormalities. Determining if the airway is compromised is important in considering the anesthetic technique. Neoadjuvant treatment before exploration should be considered if concern exists that a complete excision cannot be accomplished.
For confirmed thymoma, a median sternotomy is the incision of choice. Transcervical thymectomies were reported mostly for tumors that were discovered at the time of surgery. Lateral thoracotomies are appropriate for anterior large lateralized thymomas where controlling the pulmonary hilum is necessary. In selected patients, minimally invasive thymectomy can be safe and effective.
Noninvasive thymomas are cured by surgical excision alone in 85-90% of cases. Invasive thymoma is diagnosed by the surgeon's assessment of evidence of invasion by the tumor into the adjacent tissues. Adherent pericardium, pleura, or lung should be resected with the thymoma. Radical exenteration of the anterior mediastinum is recommended strongly for thymomas without myasthenia gravis. Special attention should be paid to avoid tumor spillage.
Adjuvant radiation therapy (RT) remains controversial.[12, 14] All series that address this issue are retrospective reviews, and the role of RT in these cases remains unclear. Some recommend it for tumors larger than 5 cm or for stage II and III tumors that have been completely resected. The benefit for a patient with a stage I tumor is marginal, at best. RT appears to decrease the recurrence rate of incompletely resected tumors.
Several series suggest that multimodality treatment (preoperative chemotherapy, surgery, and postoperative chemotherapy or RT) of stage III and IVa thymic tumors allows good long-term outcome; the neoadjuvant chemotherapy improves resectability and survival rates in these cases.[12, 16]
Metastasizing thymomas usually are treated solely with chemotherapy with cisplatin-based combination chemotherapy (doxorubicin, vincristine, cyclophosphamide, cisplatin). No consensus has been reached on the best approach in these cases.
Recurrent tumors are treated by reexcision, in addition to both chemotherapy and radiation therapy (7-year survival rate, 70%).
Bulky unresectable masses are treated primarily with chemotherapy, surgical debulking, and radiation therapy. Some studies show improved survival (especially at 5 years) with debulking, while other authors argue that this provides no additional benefit over biopsy.[17, 14]
CT is recommended as a baseline test and periodically after resection to evaluate for recurrence.
Patients older than 60 years have a higher mortality as a result of tumor growth. Pure spindle cell neoplasms seem to act as benign tumors, rarely causing death. No neoplasms smaller than 5 cm were reported to cause recurrence or death. Patients with tumors 10 cm or larger have a higher mortality. The presence of mediastinal displacement symptoms is a poor prognostic indicator.
The 10-year survival rate for stage I thymoma is 85-100%. The 10-year survival rate for stage II thymoma is 60-84%. The reported 10-year survival rate for stage III is 21-77%. Thoracic relapses after radiation occurred in 15%. The reported 10-year survival rate for stage IV is 26-47%. Thoracic relapses after radiation occurred in 50% of patients, and 90% of these relapses were outside of the radiation field.
Thymic carcinomas are cytologically malignant. They are rare tumors, and there are few specific pathologic findings to distinguish them from other histologically similar metastatic neoplasms (large cell lymphoma, seminoma, embryonal carcinoma, and sarcoma).
Most patients present with advanced disease (stage III or IV) that manifests as mediastinal masses. These masses are revealed by routine chest radiographs. They are associated more frequently with symptoms of mediastinal structural displacement and extrathoracic metastasis. Myasthenia gravis, erythroid hypoplasia, and hypogammaglobulinemia have not been reported with thymic carcinoma.
Alpha-fetoprotein and beta–human chorionic gonadotropin help in distinguishing the differential diagnosis of germ cell tumors.
Chest radiography is indicated. Computed tomography (CT) or magnetic resonance imaging (MRI) in addition to positron emission tomography (PET) scan is indicated in all patients with a suspected mass. Fine-needle aspiration (FNA) and core-needle biopsy are indicated. Mediastinoscopy provides a large tissue sample.
Immunohistochemistry provides the most useful method to differentiate thymic carcinoma from other similar neoplasms. Thymic carcinomas are typically rubbery or gritty and gray-white with areas of hemorrhage and necrosis. Cystic changes were reported in some cases. Several distinctive microscopic variants are recognized, as follows:
Lymphoepitheliomalike squamous carcinoma
Keratinizing squamous carcinoma
Basaloid squamous carcinoma
Clear cell thymic carcinoma
Complete surgical resection, if technically feasible, has the best long-term result. Involved structures (anterior pericardium, lung) should be resected en bloc with the tumor. Widely invasive tumors are best treated with radiotherapy, with or without cytotoxic drugs.
The mortality is higher than 85% in reported cases; median survival among patients with incompletely resected tumors is 12-36 months. Radiotherapy and chemotherapy have offered little therapeutic benefit.
Other Thymic Tumors
Thymic carcinoid tumors are rare (150-200 cases have been reported). Thirty percent of thymic carcinoid tumors are associated with Cushing syndrome. Inappropriate ectopic production of antidiuretic hormone, hypertrophic osteoarthropathy, and Lambert-Eaton syndrome also has been reported.
Thymic oat cell carcinoma is very rare (20% of neuroendocrine tumors). Most apparent oat cell carcinomas are metastatic tumors from occult bronchogenic neoplasm, which must be ruled out clinically.
Thymic germ cell tumors
These include the following:
Yolk sac tumors
Hodgkin lymphoma is more common; the nodular sclerosing type is the most common variant. Non-Hodgkin lymphoma has also been observed.
Myasthenia gravis is an autoimmune disorder of neuromuscular transmission in which antibodies reduce the number of acetylcholine receptors at the neuromuscular junction. The condition was first recognized by Wilks in 1877, and the term myasthenia gravis pseudoparalytica was used first by Jolly a few years after. No effective therapy existed until 1934, when Walker used physostigmine, followed by Blalock's introduction of surgical therapy.
Myasthenia gravis develops in both adults and children. Pediatric myasthenia gravis may be subclassified as follows:
Neonatal (1%) - Self-limited and due to placental transfer of antibodies from the myasthenic mother
Juvenile (9%) - Permanent
Adult myasthenia gravis may be subclassified as follows:
Mild generalized (30%)
Moderate generalized (20%)
Acute fulminating (11%) - Prominent respiratory symptoms
Late severe (9%) - Progress after 2 years of mild disease
The incidence of myasthenia gravis is 0.5-5 cases per 100,000 population, with a prevalence rate that has been on the rise for the past 40 years. All ages are at risk. The peak age at onset is 20-30 years in women and older than 50 years in men. The female-to-male ratio is 3:2 in the general population and 5:1 in young patients.
Pathophysiology and etiology
The pathophysiology involves antibody-mediated destruction of the acetylcholine receptors by induction of cross linking of the receptors, resulting in accelerated endocytosis and subsequent degradation of the receptors, with a possible role for complement-mediated end plate destruction and simple binding and blockage of the receptors by the antibodies.
Although the source of autoantibodies in myasthenia gravis is unknown, the thymus is thought to have a major role in the pathology of this disease. The thymic myoid cells, with their resemblance to embryonic muscle cells, serve as the antigen source for the development of these antibodies.
The role of the thymus is suspected on the basis of the following:
The thymus gland is abnormal in 80% of patients (60% have follicular lymphoid hyperplasia, 10-20% have thymoma)
About 30-60% of patients with thymoma have (or subsequently develop) myasthenia gravis
Acetylcholine receptor antibodies and antibodies to striated muscle have been demonstrated in the thymus of patients with myasthenia gravis
Thymectomy has a proven beneficial therapeutic role for these patients
Weakness or fatigability occurs with repetitive exercise and resolves with rest. The clinical course is unpredictable and characterized by frequent spontaneous remission and relapses.
The muscle groups involved and the degree of their involvement vary considerably over time. Ocular muscles are the most frequently involved, resulting in ptosis and diplopia, which can be exaggerated by a sustained upward gaze. Proximal muscle groups are involved more frequently than the distal groups. Deep tendon reflexes are preserved.
No single test result is uniformly positive, but combination of these tests with the clinical picture establishes the diagnosis in most patients.
Elevated acetylcholine receptor antibody titers are highly specific for myasthenia gravis. The sensitivity ranges from 64% in patients with only ocular symptoms to 89% in patients with generalized disease.
Imaging studies that may be helpful include chest radiography and computed tomography (CT) to exclude the presence of thymoma.
The results of single-fiber electromyography (EMG) have been shown to be positive in 60-75% of patients with ocular myasthenia gravis, in 90% of patients with mild generalized myasthenia gravis, and in 100% of those with moderate-to-severe disease.
Short-acting cholinesterase medications, such as edrophonium, could be used as a diagnostic test for myasthenia gravis. When administered intravenously, they produce significant improvement in muscle strength, usually within 30-60 seconds. The sensitivity of this test is approximately 85% for ocular myasthenia gravis and 95% for generalized disease.
Conditions to be considered in the differential diagnosis include the following:
Amyotrophic lateral sclerosis
Organophosphate intoxification, snakebites, and drug-induced (penicillamine, procainamide, and aminoglycoside) myasthenia
Eaton-Lambert syndrome (associated with malignancy)
Only a few drugs are available for pharmacologic treatment of myasthenia gravis.
Cholinesterase inhibitors decrease hydrolysis of acetylcholine, thereby increasing the amount of acetylcholine available in the synaptic cleft and providing symptomatic relief. They have no effect on the course of myasthenia gravis. Optimal dosage varies widely; dosing should be adjusted on a personal basis by using the minimal dose necessary to achieve an effect while avoiding muscarinic adverse effects (abdominal cramping, diarrhea, excessive salivation, diaphoresis, and bradycardia). A feared adverse effect is cholinergic crisis, which produces a depolarizing-type neuromuscular blockade that could be confused clinically with myasthenic crisis.
Specific agents include the following:
Pyridostigmine - Long-duration action (adverse effects may include nausea/vomiting, sweating, diarrhea, weakness, muscle cramps, psychosis, miosis)
Neostigmine - More rapid onset and shorter duration of action (insensitivity to this drug may develop)
Edrophonium - Very rapid onset and short duration of action; used for diagnostic purposes
Corticosteroids are usually reserved for patients who fail to respond to or do not tolerate anticholinesterase therapy. They also have been used to prepare patients for thymectomy. They provide symptomatic improvement in as many as 80% of the patients, but relapse is common after discontinuance. The risk associated with long-term steroid use is always a matter of concern.
Immunosuppression with azathioprine is used for patients who do not respond to or do not tolerate anticholinesterase therapy. The response rate is 70-80%. Adverse effects are common.
Intravenous immunoglobulin (IVIg) 1 g/kg has been shown to be effective in the treatment of exacerbations of myasthenia gravis; however, other studies did not find this approach to be superior to plasmapheresis (see below) or oral steroid therapy. Similarly, there has been insufficient evidence to suggest that IVIg is efficacious in the treatment of chronic myasthenia gravis.
Antibody removal by plasmapheresis produces symptomatic relief in as many as 90% of patients. It is extremely effective when dramatic and rapid response is necessary. Five exchanges are required. The effects last a few weeks; thus, the use of plasmapheresis is limited to the short term, such as during myasthenic crisis and in the perioperative period.
Total-body irradiation has been used successfully in thymectomized patients who were refractory to other treatments, with clinical improvement lasting more than 2 years in 40% of the reported cases.
The benefit of thymectomy is based on observation. The mechanism is still unknown, as is which patients are more likely to respond. A prospective randomized international trial to assess the role of thymectomy in myasthenia gravis is underway.
Patients are usually considered for thymectomy when they do not respond to treatment with cholinesterase inhibitors or when the adverse effects limit the benefit of this treatment.
Based on observation, patients with short duration of symptoms are most likely to benefit from the operation, which is the rationale for early consideration of patients with generalized symptoms for surgery.
Some studies report similar results with patients with isolated ocular symptoms. In these patients, thymectomy prevented the progression to generalized disease. Given the low morbidity of the transcervical approach, some surgeons recommend transcervical thymectomy for these patients.
If thymoma is present, surgery should be performed as soon as symptoms can be controlled.
Symptoms must be controlled medically before the surgery, with special attention to optimizing the respiratory mechanics. Paralyzing agents should be used with caution for anesthesia. They have a rapid onset and more marked neuromuscular block, which decreases their safety margin. In addition, the rate of recovery from the block is not enhanced by neostigmine.
Transcervical thymectomy carries low morbidity, with remission and response rates that are comparable with those of the transsternal thymectomy. Transsternal thymectomy ensures the removal of all the adjacent cervical and mediastinal fat, which may contain aberrant thymic tissue.
Complete thoracoscopic thymectomy has been shown to be feasible with comparable midterm results and less morbidity.[24, 25, 26] No prospective randomized study is available to compare it with the transsternal and transcervical approaches.
As an ideal technology for dissection in a small anatomic area, robotic thymectomy has the potential to offer minimally invasive surgery with the same result as from the more invasive "maximal thymectomy" approach. Additional advantages include minimizing pain and improving cosmesis. Five groups have reported short-term results, totaling 200 cases. Operating time ranged from 2 to 5.2 hours, morbidity was 2-10%, median hospital stay was 2-5 days, and no mortality was reported. The long-term outcomes have yet to be demonstrated.[28, 29, 30, 31, 32, 33]
Aggressive pulmonary care is provided. Anticholinesterase medication (the same as is used preoperatively) is continued after extubation. The benefit of the procedure may not be apparent for years. Mild cases may be exacerbated after thymectomy. Reoperation should be considered if incomplete resection is suspected.
Thirty years ago, 25% of patients with myasthenia gravis died of the condition. Current treatments provide a normal life expectancy for patients.
Age younger than 45 years, hyperplastic gland, and female sex have been reported as predictors of improvement after thymectomy. The presence of thymoma is associated with higher likelihood of more severe symptoms and with less improvement after thymectomy. The complete remission rate after thymectomy is 33% in general and 17% in patients with isolated ocular symptoms, compared with 8% after medical treatment, with survival advantage after thymectomy. Symptomatic improvement was reported in 80-94% of patients after thymectomy. A small percentage of patients fare worse after thymectomy or have recurrence after improvement.
The Myasthenia Gravis Foundation of America standardized the description of surgical approach into the following:
T-1 Transcervical (a) basic (b) extended
T-2 Videoscopic (a) classic (b) video-assisted thorascopic extended thymectomy (VATET)
T-3 Transsternal (a) standard (b) extended
T-4 Transsternal and transcervical
Evidence supports superior results with T-3b (50%) and T-4 (81%) techniques compared to T-1a (32%). In one study, all 15 reoperations after T-1a and T-3a revealed residual thymus, with symptomatic improvement after complete resection in 13 of these patients.[34, 35]
Blalock A, Mason MF, Morgan HJ. Myasthenia gravis and tumors of the thymic region. Ann Surg. 1939. 110:544-61.
Blalock A. Thymectomy in the treatment of myasthenia gravis. J Thorac Surg. 1944. 13:316.
Al-Shihabi BM, Jackson JM. Cervical thymic cyst. J Laryngol Otol. 1982 Feb. 96(2):181-9. [Medline].
Audhya T, Talle MA, Goldstein G. Thymopoietin radioreceptor assay utilizing lectin-purified glycoprotein from a biologically responsive T cell line. Arch Biochem Biophys. 1984 Oct. 234(1):167-77. [Medline].
Gelfand DW, Goldman AS, Law EJ, MacMillan BG, Larson D, Abston S, et al. Thymic hyperplasia in children recovering from thermal burns. J Trauma. 1972 Sep. 12(9):813-7. [Medline].
Rosai J, Sobin L. Histological typing of tumors of the thymus. World Health Organization, International classification of tumors. 1999. 9-14.
Demirci S, Turhan K, Ozsan N, Yalman D, Cakan A, Cok G, et al. Prognostic factors for survival in patients with thymic epithelial tumors. Thorac Cardiovasc Surg. 2011 Apr. 59(3):153-7. [Medline].
Spaggiari L, Casiraghi M, Guarize J. Multidisciplinary treatment of malignant thymoma. Curr Opin Oncol. 2011 Dec 2. [Medline].
Ambrogi V, Mineo TC. Active ectopic thymus predicts poor outcome after thymectomy in class III myasthenia gravis. J Thorac Cardiovasc Surg. 2011 Dec 17. [Medline].
Bressler EL, Kirkham JA. Mediastinal masses: alternative approaches to CT-guided needle biopsy. Radiology. 1994 May. 191(2):391-6. [Medline].
Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 2004 Jun 17. 350(25):2625-6. [Medline].
Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004 May. 77(5):1860-9. [Medline].
Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol. 2005 Mar. 17(2):140-6. [Medline].
Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003 Sep. 76(3):878-84; discussion 884-5. [Medline].
Friedant AJ, Handorf EA, Su S, Scott WJ. Minimally Invasive versus Open Thymectomy for Thymic Malignancies: Systematic Review and Meta-Analysis. J Thorac Oncol. 2016 Jan. 11 (1):30-8. [Medline].
Lucchi M, Ambrogi MC, Duranti L, Basolo F, Fontanini G, Angeletti CA, et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg. 2005 Jun. 79(6):1840-4. [Medline].
Cohen DJ, Ronnigen LD, Graeber GM, Deshong JL, Jaffin J, Burge JR, et al. Management of patients with malignant thymoma. J Thorac Cardiovasc Surg. 1984 Feb. 87(2):301-7. [Medline].
Walker MB. Treatment of Myasthenia gravis with physostigmine. Lancet. 1934. 1:1200.
Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012 Dec 12. 12:CD002277. [Medline].
Durelli L, Ferrio MF, Urgesi A, Poccardi G, Ferrero B, Bergamini L. Total body irradiation for myasthenia gravis: a long-term follow-up. Neurology. 1993 Nov. 43(11):2215-21. [Medline].
Frist WH, Thirumalai S, Doehring CB, Merrill WH, Stewart JR, Fenichel GM, et al. Thymectomy for the myasthenia gravis patient: factors influencing outcome. Ann Thorac Surg. 1994 Feb. 57(2):334-8. [Medline].
Newsom-Davis J, Cutter G, Wolfe GI, Kaminski HJ, Jaretzki A 3rd, Minisman G. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci. 2008. 1132:344-7. [Medline].
Nieto IP, Robledo JP, Pajuelo MC, Montes JA, Giron JG, Alonso JG, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg. 1999 Jun. 67(6):1568-71. [Medline].
Ruckert JC, Gellert K, Muller JM. Operative technique for thoracoscopic thymectomy. Surg Endosc. 1999 Sep. 13(9):943-6. [Medline].
Tomulescu V, Ion V, Kosa A, Sgarbura O, Popescu I. Thoracoscopic thymectomy mid-term results. Ann Thorac Surg. 2006 Sep. 82(3):1003-7. [Medline].
Marulli G, Maessen J, Melfi F, Schmid TA, Keijzers M, Fanucchi O, et al. Multi-institutional European experience of robotic thymectomy for thymoma. Ann Cardiothorac Surg. 2016 Jan. 5 (1):18-25. [Medline]. [Full Text].
Ashton RC Jr, McGinnis KM, Connery CP, Swistel DG, Ewing DR, DeRose JJ Jr. Totally endoscopic robotic thymectomy for myasthenia gravis. Ann Thorac Surg. 2003 Feb. 75(2):569-71. [Medline].
Rea F, Marulli G, Bortolotti L, Feltracco P, Zuin A, Sartori F. Experience with the "da Vinci" robotic system for thymectomy in patients with myasthenia gravis: report of 33 cases. Ann Thorac Surg. 2006 Feb. 81(2):455-9. [Medline].
Savitt MA, Gao G, Furnary AP, Swanson J, Gately HL, Handy JR. Application of robotic-assisted techniques to the surgical evaluation and treatment of the anterior mediastinum. Ann Thorac Surg. 2005 Feb. 79(2):450-5; discussion 455. [Medline].
Cakar F, Werner P, Augustin F, Schmid T, Wolf-Magele A, Sieb M. A comparison of outcomes after robotic open extended thymectomy for myasthenia gravis. Eur J Cardiothorac Surg. 2007 Mar. 31(3):501-4; discussion 504-5. [Medline].
Ruckert JC, Ismail M, Swierzy M, Sobel H, Rogalla P, Meisel A. Thoracoscopic thymectomy with the da Vinci robotic system for myasthenia gravis. Ann N Y Acad Sci. 2008. 1132:329-35. [Medline].
Castle SL, Kernstine KH. Robotic-assisted thymectomy. Semin Thorac Cardiovasc Surg. 2008. 20(4):326-31. [Medline].
Jaretzki A 3rd. Thymectomy for myasthenia gravis: analysis of controversies--patient management. Neurologist. 2003 Mar. 9(2):77-92. [Medline].
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000 Jul. 70(1):327-34. [Medline].